Skip to content

Depreciation at other companies

Illumina logo
IlluminaILMN
Revvity logo
RevvityRVTY
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Charles River Laboratories logo
Charles River LaboratoriesCRL

Other financials

Income statement

See full
Revenue$37.2M+0.1%
Gross profit$12.8M+1,037%
Operating income-$8.4M+98.1%
Net income-$8.3M+98.1%
EPS (diluted)-$0.03+97.9%

Balance sheet

See full
Cash & equivalents$57.9M-4.7%
Total debt$59.3M+12.1%
Total equity$2.4M-97.4%
Total assets$782.4M-9.1%

Cash flow

See full
Operating cash flow-$44.7M-1.4%
CapEx$3.0M+119%
Free cash flow-$47.7M-5.0%

Valuation

See full
Market cap$496.96M+30.4%
Enterprise value$498.38M+33.5%
P/S3.1×+0.6×

Profitability

See full
Gross margin37.5%+21.3pp
Operating margin-83.3%-38.2pp
Net margin-80.3%-36.1pp
FCF margin-72.6%-20.0pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio5.7×-1.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacific Biosciences of California's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacific Biosciences of California's depreciation?
Pacific Biosciences of California (PACB) reported depreciation of $2.2M in Q1 2026.
How has Pacific Biosciences of California's depreciation changed year-over-year?
Pacific Biosciences of California's depreciation decreased by 57.1% year-over-year, from $5.13M to $2.2M.
What is the long-term trend for Pacific Biosciences of California's depreciation?
Over 4 years (2021 to 2025), Pacific Biosciences of California's depreciation has grown at a 15.9% compound annual growth rate (CAGR), from $7.2M to $12.99M.